Semaglutide vs Tirzepatide: Comparing GLP-1 Therapies

The GLP 1 receptor agonist class has fundamentally reshaped how we treat type 2 diabetes and obesity. Two molecules dominate the landscape: semaglutide (Novo Nordisk's Ozempic and Wegovy) and tirzepatide (Eli Lilly's Mounjaro and Zepbound). Both target the GLP 1 receptor, but their pharmacological profiles differ in meaningful ways, and understanding those differences is essential for choosing the right therapy for each patient.

Semaglutide is a selective GLP 1 receptor agonist. It mimics the action of your body's own GLP 1, binding to receptors in the pancreas (where it stimulates glucose dependent insulin secretion), the brain (where it promotes satiety through hypothalamic and brainstem circuits), and the GI tract (where it slows gastric emptying). It lasts about a week in the body thanks to a C 18 fatty acid side chain that binds albumin (Lau et al., 2015, Journal of Medicinal Chemistry; PMID: 26308095).

Tirzepatide does something different. It is a dual GIP/GLP 1 receptor agonist, the first approved molecule in this class. On top of GLP 1 receptor activation, tirzepatide also potently activates glucose dependent insulinotropic polypeptide (GIP) receptors. GIP signaling brings complementary metabolic benefits: enhanced insulin secretion, improved fat metabolism, and potentially direct effects on adipose tissue that promote fat utilization. The GIP component may also help reduce some of the nausea that comes with pure GLP 1 agonism (Samms et al., 2021, Diabetes; PMID: 34376573).

The STEP and SURMOUNT trial programs give us the best comparative data, though direct head to head trials between these two molecules have been limited. In the STEP 1 trial, semaglutide 2.4 mg (Wegovy) produced a mean weight loss of 14.9% versus 2.4% with placebo over 68 weeks (Wilding et al., 2021, NEJM; PMID: 33567185). The STEP 5 trial showed durability, with participants maintaining a 15.2% weight reduction at 104 weeks. Tirzepatide's numbers were even more impressive. In SURMOUNT 1, the highest dose (15 mg) produced a mean weight loss of 22.5% versus 2.4% with placebo over 72 weeks (Jastreboff et al., 2022, NEJM; PMID: 35658024). The 10 mg dose hit 19.5%, and even the lowest 5 mg dose reached 15.0%, which is comparable to semaglutide's maximum dose. Cross trial comparisons always come with caveats (different patient populations, endpoints, and timeframes), but the data consistently suggests tirzepatide produces greater absolute weight loss, likely because of the additive effects of dual agonism.

Both molecules deliver excellent glycemic control. In the SURPASS trials, tirzepatide reduced HbA1c by 2.0 to 2.6% depending on dose, with up to 97% of patients getting below 7.0%. Semaglutide in the SUSTAIN trials reduced HbA1c by 1.5 to 1.8%. The SURPASS 2 trial, which directly compared tirzepatide to semaglutide 1 mg, showed tirzepatide was superior at all doses for both HbA1c reduction and weight loss (Frias et al., 2021, NEJM; PMID: 34170647).

On the cardiovascular front, semaglutide has a clear advantage in terms of proven benefit. The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events (MACE) in overweight and obese adults without diabetes (Lincoff et al., 2023, NEJM; PMID: 37952131). That was a landmark finding. Tirzepatide's cardiovascular outcomes trial (SURPASS CVOT) is still ongoing, with results expected in late 2026. Early metabolic signals are encouraging, but we do not have definitive MACE data yet.

Both molecules share a similar gastrointestinal side effect profile, which comes with the class. Nausea affects about 44% of patients on semaglutide versus 25 to 33% on tirzepatide (dose dependent). Vomiting runs about 24% with semaglutide and 10 to 15% with tirzepatide. Diarrhea rates are similar at around 30% for both, while constipation is slightly higher with tirzepatide. The lower nausea and vomiting rates with tirzepatide may be attributable to the GIP component's modulatory effects on the emetic pathway. Both require gradual dose titration over 16 to 20 weeks to minimize GI side effects. Rare but serious risks include pancreatitis (under 0.5%), gallbladder disease, and a theoretical concern about medullary thyroid carcinoma based on rodent studies (boxed warning for both). Neither should be used in patients with a personal or family history of MTC or MEN2 syndrome.

From a practical standpoint, both are once weekly subcutaneous injections, so convenience is a wash. Semaglutide follows a 4 week escalation schedule (0.25, 0.5, 1.0, 1.7, then 2.4 mg for weight management). Tirzepatide has a similar pattern with a few more intermediate steps (2.5, 5, 7.5, 10, 12.5, then 15 mg), which some clinicians find allows more granular titration. Both have faced supply constraints due to unprecedented demand, though as of early 2026 supply has largely stabilized with some regional shortages persisting. Insurance coverage varies widely, and prior authorization is common for weight management indications. For compounded versions, providers should stay current on the regulatory status following the FDA's 2024 decisions. The Peptide Association's regulatory updates track this evolving landscape.

So which one should you choose? If cardiovascular risk reduction is a primary goal, semaglutide has established MACE benefit. If the patient has a history of GI sensitivity, semaglutide may also be preferable given lower overall discontinuation rates in real world data. If maximum weight loss is the goal, or the patient has significant insulin resistance, tirzepatide's dual mechanism may offer advantages. And if GI tolerability during titration is a concern, tirzepatide's lower nausea rates could tip the balance. Ultimately, both are transformative therapies, and the decision should be individualized based on the patient's metabolic profile, comorbidities, insurance coverage, and treatment goals.